NO920040L - SYRELABILE LEFT MOLECULES - Google Patents
SYRELABILE LEFT MOLECULESInfo
- Publication number
- NO920040L NO920040L NO92920040A NO920040A NO920040L NO 920040 L NO920040 L NO 920040L NO 92920040 A NO92920040 A NO 92920040A NO 920040 A NO920040 A NO 920040A NO 920040 L NO920040 L NO 920040L
- Authority
- NO
- Norway
- Prior art keywords
- aralkyl
- aryl
- lower alkyl
- alkylene
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Mushroom Cultivation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
This invention relates to the field of immune therapy of cancer, more specifically to immunoconjugates of a cytotoxic moiety with a targeting moiety, more specifically to immunoconjugates of antibodies or fragments or functional derivatives of antibodies coupled to a cytotoxic substance such as drugs, toxins or radioisotopes. It especially relates to the release of substances bound to a targeting moiety through the use of acid-cleavable linker molecules derived from compounds of formula I. <CHEM> wherein: R1 = H, lower alkyl, -N-lower alkyl, -O-lower alkyl, -S-lower alkyl, -N-lower aralkyl, -O-lower aralkyl, -S-lower aralkyl, -N-lower alkylene, -O-lower alkylene, -S-lower alkylene, -N-lower aryl, -O-lower aryl, -S-lower aryl, R2 = H, lower alkyl, lower aralkyl, lower aryl R3 is <CHEM> or another chemical structure which is able to decolize the lone pair electrons of the Nitrogen and R4 is a pendant reactive group, capable of linking R3 to a carrier molecule, a proteinaceous substance, an antibody (fragment), a polymer or a nucleic acid.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90203526 | 1990-12-31 |
Publications (4)
Publication Number | Publication Date |
---|---|
NO920040D0 NO920040D0 (en) | 1992-01-02 |
NO920040L true NO920040L (en) | 1992-07-01 |
NO180417B NO180417B (en) | 1997-01-06 |
NO180417C NO180417C (en) | 1997-04-16 |
Family
ID=8205218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO920040A NO180417C (en) | 1990-12-31 | 1992-01-02 | Acid-labile linker molecules |
Country Status (17)
Country | Link |
---|---|
US (1) | US5306809A (en) |
EP (1) | EP0495265B1 (en) |
JP (1) | JPH04334377A (en) |
KR (1) | KR920012063A (en) |
AT (1) | ATE109476T1 (en) |
AU (1) | AU646121B2 (en) |
CA (1) | CA2058595A1 (en) |
DE (1) | DE69103255T2 (en) |
DK (1) | DK0495265T3 (en) |
ES (1) | ES2061166T3 (en) |
FI (1) | FI101678B1 (en) |
HU (1) | HUT60484A (en) |
IE (1) | IE65406B1 (en) |
NO (1) | NO180417C (en) |
NZ (1) | NZ241217A (en) |
PT (1) | PT99954B (en) |
ZA (1) | ZA9110203B (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5505931A (en) * | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
EP0638583A1 (en) * | 1993-08-13 | 1995-02-15 | Hoechst Aktiengesellschaft | Aminosugar active substances, a process for their preparation and use as pharmaceuticals |
DE4433890C2 (en) * | 1994-09-22 | 1999-02-18 | Deutsches Krebsforsch | Conjugate of an active ingredient and a native protein that is not considered foreign to the body |
PT871490E (en) * | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | BRIDGED HIDRAZONE LIGANTS |
DE19636889A1 (en) * | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastic transferrin and albumin conjugates of cytostatic compounds from the group of the anthracyclines, alkylating agents, antimetabolites and cisplatin analogues and medicaments containing them |
US6030997A (en) * | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
US6800616B2 (en) * | 1998-02-26 | 2004-10-05 | Supergen, Inc. | Treatment of HIV infections |
CA2248592A1 (en) | 1998-08-31 | 2000-02-29 | Christopher D. Batich | Microspheres for use in the treatment of cancer |
US6140015A (en) * | 1998-12-10 | 2000-10-31 | International Business Machines Corporation | Photoresist compositions with pendant polar-functionalized aromatic groups and acid-labile branching |
TWI242000B (en) * | 1998-12-10 | 2005-10-21 | Univ Southern California | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
CA2358420C (en) * | 1999-03-11 | 2010-03-16 | Ardenia Investments Ltd. | New compounds for the treatment of cancer |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
BRPI0003386B8 (en) * | 2000-08-08 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | homo- or heterodimeric prodrugs useful in treating diseases or disorders mediated by phosphodiesterases; pharmaceutical compositions containing the prodrug or its pharmaceutical acceptable salts; process of obtaining these prodrugs |
HUP0303719A2 (en) * | 2000-10-16 | 2004-03-01 | Neopharm, Inc. | Liposomal pharmaceutical composition of mitoxantrone and process for their preparation |
EP2335728A1 (en) | 2001-05-11 | 2011-06-22 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
GB0116143D0 (en) * | 2001-07-02 | 2001-08-22 | Amersham Pharm Biotech Uk Ltd | Chemical capture reagent |
KR100507968B1 (en) * | 2001-08-18 | 2005-08-17 | 한국과학기술연구원 | Anti-cancer drug-chitosan complex forming self-aggregates and preparation method thereof |
EP1501352B1 (en) * | 2001-12-14 | 2015-02-18 | The University Of Wyoming | Controlled release of oxycodone |
US8361464B2 (en) | 2002-03-01 | 2013-01-29 | Immunomedics, Inc. | Anthracycline-Antibody Conjugates for Cancer Therapy |
AU2003220091B2 (en) * | 2002-03-08 | 2006-02-16 | Emory University | Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis |
US20050069551A1 (en) * | 2002-03-08 | 2005-03-31 | Emory University | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis |
JP2005529931A (en) * | 2002-05-24 | 2005-10-06 | マイラス コーポレイション | Reversible modification of membrane interactions |
CN1733314A (en) * | 2004-08-11 | 2006-02-15 | 张阳德 | Process for preparing cerebrose albumin magnetic adriamycin nanometer particle |
WO2006052900A2 (en) | 2004-11-09 | 2006-05-18 | University Of Southern California | Targeted innate immunity |
EP2311880A3 (en) | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
KR20090091145A (en) | 2006-10-27 | 2009-08-26 | 웨이-치앙 션 | Lipidized interferon and uses thereof |
CN104043123B (en) * | 2007-01-25 | 2019-08-13 | 达娜-法勃肿瘤研究所公司 | Purposes of the anti-egfr antibodies in the mutant mediated disease for the treatment of EGFR |
CN101688229B (en) * | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | Treatment method using EGFR antibodies and SRC inhibitors and related formulations |
CN101896503B (en) | 2007-08-14 | 2018-05-22 | 路德维格癌症研究所有限公司 | The monoclonal antibody 175 and its derivative and purposes of targeting EGF receptor |
WO2010011684A2 (en) * | 2008-07-21 | 2010-01-28 | The Regents Of The University Of California | Prodrug and fluoregenic compositions and methods for using the same |
US9051354B2 (en) | 2009-03-17 | 2015-06-09 | The University Of Tokyo | Protein charge regulator and protein-encapsulating polymer micelle complex |
WO2010111664A1 (en) * | 2009-03-26 | 2010-09-30 | Institute For Systems Biology | Improved method to determine protein interaction sites |
AU2010268690B2 (en) | 2009-07-03 | 2011-11-10 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
US9315581B2 (en) | 2009-12-23 | 2016-04-19 | A Vipep Pty Limited | Immuno-conjugates and methods for producing them |
CN103080125A (en) | 2010-07-02 | 2013-05-01 | 安吉奥开米公司 | Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
DK2744931T3 (en) | 2011-08-18 | 2018-08-06 | Affinity Biosciences Pty Ltd | SOLUBLE POLYPEPTIDES |
PT2802606T (en) | 2012-01-10 | 2018-07-13 | Biogen Ma Inc | Enhancement of transport of therapeutic molecules across the blood brain barrier |
GB201202268D0 (en) | 2012-02-09 | 2012-03-28 | Medical Res Council | Intracellular immunity |
WO2014057436A2 (en) | 2012-10-10 | 2014-04-17 | Adamed Sp. Z O.O. | Anticancer conjugate |
WO2014124227A1 (en) | 2013-02-07 | 2014-08-14 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
WO2014141094A1 (en) | 2013-03-14 | 2014-09-18 | Adamed Sp. Z O.O. | Anticancer conjugate |
EP3104857A4 (en) | 2014-02-14 | 2017-10-11 | The Regents of The University of California | Cyclic peroxides as prodrugs for selective delivery of agents |
CA2963218C (en) | 2014-10-03 | 2023-10-24 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
EA034582B1 (en) | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Sirp-alpha variant constructs and use thereof |
DK3331902T3 (en) | 2015-08-07 | 2021-07-26 | Alx Oncology Inc | CONSTRUCTIONS WITH A SIRP ALPHA DOMAIN OR VARIANT THEREOF |
JP6810146B2 (en) | 2015-11-24 | 2021-01-06 | トランスフェール プリュ エス.ウ.セ. | Peptide Compounds and Peptide Conjugates for the Treatment of Cancer with Receptor-Mediated Chemotherapy |
WO2018118015A1 (en) | 2016-12-19 | 2018-06-28 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
US10800817B2 (en) | 2016-12-19 | 2020-10-13 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
BR112021024003A2 (en) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Cancer treatment methods with sirp alpha-fc fusion in combination with an immune checkpoint inhibitor |
US11180534B1 (en) | 2021-06-04 | 2021-11-23 | Morehouse School Of Medicine | Compositions and methods for treating SARS-CoV-2 infections |
US20230277682A1 (en) * | 2022-01-14 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Verrucarin a derivatives and antibody drug conjugates thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631190A (en) * | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4744981A (en) * | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
US4997913A (en) * | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
US5140013A (en) * | 1989-11-28 | 1992-08-18 | Universite Laval | Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers |
-
1991
- 1991-12-27 FI FI916131A patent/FI101678B1/en active
- 1991-12-27 JP JP3361486A patent/JPH04334377A/en active Pending
- 1991-12-28 HU HU914133A patent/HUT60484A/en unknown
- 1991-12-30 DK DK91203439.4T patent/DK0495265T3/en active
- 1991-12-30 CA CA002058595A patent/CA2058595A1/en not_active Abandoned
- 1991-12-30 DE DE69103255T patent/DE69103255T2/en not_active Expired - Fee Related
- 1991-12-30 PT PT99954A patent/PT99954B/en not_active IP Right Cessation
- 1991-12-30 AU AU90098/91A patent/AU646121B2/en not_active Ceased
- 1991-12-30 ES ES91203439T patent/ES2061166T3/en not_active Expired - Lifetime
- 1991-12-30 ZA ZA9110203A patent/ZA9110203B/en unknown
- 1991-12-30 AT AT91203439T patent/ATE109476T1/en active
- 1991-12-30 EP EP91203439A patent/EP0495265B1/en not_active Expired - Lifetime
- 1991-12-30 IE IE456791A patent/IE65406B1/en not_active IP Right Cessation
- 1991-12-30 KR KR1019910025982A patent/KR920012063A/en not_active Application Discontinuation
- 1991-12-31 US US07/815,671 patent/US5306809A/en not_active Expired - Fee Related
-
1992
- 1992-01-02 NO NO920040A patent/NO180417C/en unknown
- 1992-01-06 NZ NZ241217A patent/NZ241217A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP0495265B1 (en) | 1994-08-03 |
PT99954A (en) | 1993-06-30 |
FI916131A (en) | 1992-07-01 |
DE69103255D1 (en) | 1994-09-08 |
FI916131A0 (en) | 1991-12-27 |
AU9009891A (en) | 1993-01-28 |
JPH04334377A (en) | 1992-11-20 |
FI101678B (en) | 1998-08-14 |
US5306809A (en) | 1994-04-26 |
NO920040D0 (en) | 1992-01-02 |
PT99954B (en) | 1999-06-30 |
FI101678B1 (en) | 1998-08-14 |
ATE109476T1 (en) | 1994-08-15 |
HUT60484A (en) | 1992-09-28 |
NO180417B (en) | 1997-01-06 |
NO180417C (en) | 1997-04-16 |
AU646121B2 (en) | 1994-02-10 |
ZA9110203B (en) | 1993-01-27 |
KR920012063A (en) | 1992-07-25 |
EP0495265A1 (en) | 1992-07-22 |
IE65406B1 (en) | 1995-10-18 |
HU914133D0 (en) | 1992-03-30 |
ES2061166T3 (en) | 1994-12-01 |
IE914567A1 (en) | 1992-07-01 |
CA2058595A1 (en) | 1992-07-01 |
DK0495265T3 (en) | 1995-01-02 |
NZ241217A (en) | 1993-12-23 |
DE69103255T2 (en) | 1994-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO920040D0 (en) | SYRELABILE LEFT MOLECULES | |
MXPA03010432A (en) | Cytotoxic cd44 antibody immunoconjugates. | |
FI912285A0 (en) | NYA BIFUNKTIONELLA KOPPLINGSFOERENINGAR, KONJUGAT OCH FOERFARANDEN FOER FRAMSTAELLNING AV DESSA. | |
ATE294592T1 (en) | CONJUGATES CONTAINING THIOETHER | |
KR900002803A (en) | Cytotoxic drug conjugates | |
IL64722A (en) | Immunoglobulin conjugates,their preparation and pharmaceutical compositions containing them | |
FI915780A0 (en) | MAERKTAE, MODIFIED OLIGONUCLEOTIDER. | |
WO2004041307A3 (en) | Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy | |
WO1996040664A3 (en) | Preparation of immunogens and other conjugates of drugs | |
HUT70481A (en) | Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them |